The Feinstein Institute for Medical Research will be partnering with the University of Notre Dame on a series of research projects to study various diseases and modernized treatment options, North Shore-LIJ Health System officials said Monday.
The two institutions will co-publish their results, commercialize its inventions and other intellectual properties and offer an exchange program for students to research in other laboratories, officials said.
“Each of our institutions brings with it a unique set of research skills and capabilities,” said Dr. Kevin J. Tracey, president of the Feinstein Institute. “By working together, we will be able to make real advances in addressing a number of serious health challenges.”
Feinstein and Notre Dame also have a partnership through the Cleveland Clinic Innovation Alliance, a network of health-care organizations that combine research, clinical investigation and technology development and commercialization, officials said.
Among the first projects Feinstein and Notre Dame will undertake are studies in sepsis, a condition in which the body has an adverse reaction when exposed to bacteria or infection; bioelectronic medicine, in which devices that stimulate nerves are used to treat diseases; and the development of exosome biology, which officials said could make an impact on degenerative brain diseases like Alzheimer’s or Parkinson’s.
“Being able to work closely with the world-class clinical researchers in their specialties at the Feinstein Institute will allow our analytical scientists and engineers to continue to be a powerful means for good in the world by solving problems of immediate interest to physicians and hospitals,” said Robert Bernhard, the vice president for research at the University of Notre Dame. “We are grateful for the opportunity of this partnership and look forward to the fruitful results that this collaboration will bring.”
